Aurinia Pharmaceuticals announced a significant restructuring plan on November 7, 2024, which includes a 45% workforce reduction aimed at improving operational efficiency and achieving over $40 million in annual cash savings, while also reporting its financial results for the quarter ended September 30, 2024.